In a report released on January 4, Jailendra Singh from Truist Financial maintained a Buy rating on Progyny (PGNY – Research Report), with a price target of $47.00. The company’s shares closed last Friday at $36.30.
Singh covers the Healthcare sector, focusing on stocks such as R1 RCM, Evolent Health, and Agilon Health. According to TipRanks, Singh has an average return of -15.2% and a 33.54% success rate on recommended stocks.
Currently, the analyst consensus on Progyny is a Strong Buy with an average price target of $46.25, a 27.41% upside from current levels. In a report released on January 5, BTIG also maintained a Buy rating on the stock with a $45.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Progyny’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $280.89 million and a net profit of $15.9 million. In comparison, last year the company earned a revenue of $205.37 million and had a net profit of $13.21 million
Based on the recent corporate insider activity of 94 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PGNY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Progyny (PGNY) Company Description:
Progyny, Inc. is a medical device company, which engages in the field of reproductive medicine, translating scientific discoveries related to early embryo development into clinical tools. Its services include egg freezing, IVF treatment, surrogacy, podcast, adoption, and Eeva Test. The company was founded on April 03, 2008 and is headquartered in New York, NY.
Read More on PGNY:
- Barclays starts healthcare technology, distribution with Neutral view
- Progyny initiated with an Outperform at Barclays
- Progyny management to meet with BTIG
- Progyny price target lowered to $49 from $57 at JPMorgan
- Progyny, Inc. to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
